Cochrane · systematic review · CD011057
Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse
Temmingh, HS, Williams, T, Siegfried, N, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
17
current version
GRADE rated
15
No studies
2
Included studies
NR
No studies 2 · 11.8%Ungraded 0 · 0%Very low 12 · 70.6%Low 3 · 17.6%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
RISPERIDONE versus CLOZAPINE ‐ all data short term for people with severe mental illness and co‐occurring substance misuse
Population: for people with serious mental illness and co‐occurring substance misuse
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: positive symptoms ‒average endpoint score (PANSS positive subscale, lower = better) RISPERIDONE vs CLOZAPINE ‐ all data short term | no estimate extracted | 1 study · 36 participants | Very low Downgraded: risk of bias |
Substance use: improvement ‒ (at least 20% reduction in use, TLFB scale) RISPERIDONE vs CLOZAPINE ‐ all data short term | RR 1 [0.3, 3.35] | 1 study · 14 participants | Very low Downgraded: risk of bias, imprecision |
Subjective well‐being: Subjective well‐being under neuroleptics scale ‒ average endpoint scores (SWN scale, higher = better) RISPERIDONE vs CLOZAPINE ‐ all data short term | no estimate extracted | 1 study · 36 participants | Very low Downgraded: risk of bias |
Craving for substances: Marijuana Craving Questionnaire ‒ average endpoint scores (MCQ, lower = better) RISPERIDONE vs CLOZAPINE ‐ all data short term | no estimate extracted | 1 study · 28 participants | Very low Downgraded: risk of bias |
Adherence to antipsychotic medication: discontinued medication RISPERIDONE vs CLOZAPINE ‐ all data short term | RR 4.05 [0.21, 78.76] | 1 study · 36 participants | Very low Downgraded: risk of bias |
Adverse effects. 1. Movement disorders ‐ any extrapyramidal RISPERIDONE vs CLOZAPINE ‐ all data short term | RR 2.71 [0.3, 24.08] | 2 studies · 50 participants | Very low Downgraded: risk of bias, imprecision |
Leaving the study early ‒ any reason RISPERIDONE vs CLOZAPINE ‐ all data short term | RR 0.49 [0.1, 2.51] | 2 studies · 45 participants | Very low Downgraded: risk of bias, imprecision |
RISPERIDONE versus OLANZAPINE ‒ short‐ and long‐term data for people with severe mental illness and co‐occurring substance misuse
Population: people with serious mental illness and co‐occurring substance misuse
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | 1 study · 37 participants | Very low Downgraded: risk of bias |
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision |
Subjective well‐being RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | NR | No studies |
Craving for substances: 2. Drug Desires Questionnaire‐ average endpoint scores (DDQ, lower = better) RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | 1 study · 41 participants | Very low Downgraded: risk of bias, imprecision |
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | NR | No studies |
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | no estimate extracted | 1 study · 16 participants | Very low Downgraded: risk of bias, imprecision |
Leaving study early: any reason RISPERIDONE vs OLANZAPINE ‒ short‐ and long‐term data | RR 0.68 [0.34, 1.35] | 2 studies · 77 participants | Very low Downgraded: risk of bias, imprecision |
RISPERIDONE versus PERHENAZINE ‒ long‐term data for people with severe mental illness and co‐occurring substance misuse
Population: people with severe mental illness and co‐occurring substance misuse
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: any reason RISPERIDONE vs PERHENAZINE ‒ long‐term data | RR 1.05 [0.92, 1.2] | 1 study · 281 participants | Low Downgraded: risk of bias |
RISPERIDONE versus QUETIAPINE ‒ short‐ and long‐term data for people with severe mental illness and co‐occurring substance misuse
Population: people with severe mental illness and co‐occurring substance misuse
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: 1. any reason, long term (>12 months) RISPERIDONE vs QUETIAPINE ‒ short‐ and long‐term data | RR 0.96 [0.86, 1.07] | 1 study · 294 participants | Low Downgraded: risk of bias, imprecision |
RISPERIDONE versus ZIPRASIDONE ‒ long‐term data (> 12 months) for people with severe mental illness and co‐occurring substance misuse
Population: people with severe mental illness and co‐occurring substance misuse
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Leaving the study early: any reason RISPERIDONE vs ZIPRASIDONE ‒ long‐term data (> 12 months) | RR 0.96 [0.85, 1.1] | 1 study · 240 participants | Low Downgraded: risk of bias |